Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2020

October 2020 | 326 pages | ID: CBC99D7D3A1EN
Global Markets Direct

Abstracts

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease - Pipeline Review, H2 2020, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.
Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 13, 18, 1, 25, 17 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.
Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
• The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Chronic Kidney Disease - Overview
Chronic Kidney Disease - Therapeutics Development
Chronic Kidney Disease - Therapeutics Assessment
Chronic Kidney Disease - Companies Involved in Therapeutics Development
Chronic Kidney Disease - Drug Profiles
Chronic Kidney Disease - Dormant Projects
Chronic Kidney Disease - Discontinued Products
Chronic Kidney Disease - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algernon Pharmaceuticals Inc, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algomedix Inc, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Allena Pharmaceuticals Inc, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Annji Pharmaceutical Co Ltd, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Arch Biopartners Inc, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Aronora Inc, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BioAegis Therapeutics Inc, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cadila Healthcare Ltd, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H2 2020
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020